BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol 2018;36:265-71. [PMID: 29306556 DOI: 10.1016/j.urolonc.2017.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Bi F, Tan W, Jian L, Yu X. A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1127448] [Reference Citation Analysis]
2 Cheng M, Duzgol C, Kim TH, Ghafoor S, Becker AS, Causa Andrieu PI, Gangai N, Jiang H, Hakimi AA, Vargas HA, Woo S. Sarcomatoid renal cell carcinoma: MRI features and their association with survival. Cancer Imaging 2023;23:16. [PMID: 36793052 DOI: 10.1186/s40644-023-00535-0] [Reference Citation Analysis]
3 Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022;10. [PMID: 36549781 DOI: 10.1136/jitc-2022-005445] [Reference Citation Analysis]
4 Shan L, Shao X, Gu L, Wu M, Lin P, Yu Z, Chen Q, Zhu D. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.922150] [Reference Citation Analysis]
5 Richter I, Hraboš A, Dvořák J, Al-samsan S, Bartoš J, Šámal V. Avelumab plus axitinib combination in treating metastatic renal cell carcinoma. Onkologie 2022;16:263-266. [DOI: 10.36290/xon.2022.050] [Reference Citation Analysis]
6 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
7 Al-juhaishi T, Deng X, Bandyopadhyay D, Paul A. The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis. Cureus 2022. [DOI: 10.7759/cureus.25395] [Reference Citation Analysis]
8 Fontes-Sousa M, Magalhães H, Oliveira A, Carneiro F, Dos Reis FP, Madeira PS, Meireles S. Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? Adv Ther 2022;39:1107-25. [PMID: 35025061 DOI: 10.1007/s12325-021-02007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
10 Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther 2021;:1-14. [PMID: 34291700 DOI: 10.1080/14737140.2021.1959319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol 2020;40:76-85. [PMID: 32130969 DOI: 10.1016/j.semnephrol.2019.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
12 Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 2021;13:685-92. [PMID: 33823678 DOI: 10.2217/imt-2020-0323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol 2021;10:1581-7. [PMID: 33850792 DOI: 10.21037/tau-20-1125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yang T, Wu Y, Zuo Y, Fu S, Xu Z, Yu N. Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients. Transl Androl Urol 2021;10:754-64. [PMID: 33718077 DOI: 10.21037/tau-20-1192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Donskov F. Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need. Ann Transl Med 2021;9:97. [PMID: 33569399 DOI: 10.21037/atm-20-7009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, Mariathasan S, Green M, Tayama D, Hegde PS, Schiff C, Huseni MA, Rini B. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 2020;38:803-817.e4. [PMID: 33157048 DOI: 10.1016/j.ccell.2020.10.011] [Cited by in Crossref: 173] [Cited by in F6Publishing: 143] [Article Influence: 57.7] [Reference Citation Analysis]
17 Park JJ, Kellezi O, Hamasha R, Ali A, Alva AS. Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. Cancer Treat Res Commun 2020;25:100251. [PMID: 33310369 DOI: 10.1016/j.ctarc.2020.100251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Han C, Xu B, Zhou L, Li L, Lu C, Yu GP, Liu YS. LINC02738 Participates in the Development of Kidney Cancer Through the miR-20b/Sox4 Axis. Onco Targets Ther 2020;13:10185-96. [PMID: 33116600 DOI: 10.2147/OTT.S262046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Gan CL, Dudani S, Heng DYC. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. Cancer J 2020;26:365-75. [PMID: 32947304 DOI: 10.1097/PPO.0000000000000468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dionese M, Pierantoni F, Maruzzo M, Bimbatti D, Deppieri FM, Maran M, Gardiman MP, Basso U. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. Anticancer Drugs 2021;32:222-5. [PMID: 32868643 DOI: 10.1097/CAD.0000000000000991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Thana M, Wood LA. First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review. KCA 2020;4:81-92. [DOI: 10.3233/kca-190076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zhu H, Zhao S, Zuo C, Ren F. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation. AJR Am J Roentgenol 2020;215:645-51. [PMID: 32755159 DOI: 10.2214/AJR.19.22467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Hou G, Li X, Zheng Y, Liu P, Yan F, Ju D, Zhang G, Zheng W, Gao M, Hou N, Yuan J, Wang F, Yuan J. Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study. Int J Clin Oncol 2020;25:1356-63. [PMID: 32361824 DOI: 10.1007/s10147-020-01681-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol 2020;20:14. [PMID: 32070319 DOI: 10.1186/s12894-020-0584-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
26 Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E408. [PMID: 32050629 DOI: 10.3390/cancers12020408] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
27 Bonadioa RC, Velho PI, Marta GN, Nardo M, Souza MC, Muniz DQ, Bezerra RO, Bispo RK, Faraj SF, Bastos DA, Dzik C. Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable? Ecancermedicalscience 2019;13:973. [PMID: 31921344 DOI: 10.3332/ecancer.2019.973] [Reference Citation Analysis]
28 Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol 2019;71:616-30. [PMID: 31195064 DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 198] [Cited by in F6Publishing: 209] [Article Influence: 49.5] [Reference Citation Analysis]
29 Zhang H, Majeed NK, Sharifi R, Guzman G. A Case of Sarcomatoid Renal Cell Carcinoma With Osseous Metaplasia and Papillary Renal Cell Carcinoma Metastasis. Clin Pathol 2019;12:2632010X19848005. [PMID: 31206101 DOI: 10.1177/2632010X19848005] [Reference Citation Analysis]
30 Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. [PMID: 31079938 DOI: 10.1016/S0140-6736(19)30723-8] [Cited by in Crossref: 613] [Cited by in F6Publishing: 578] [Article Influence: 153.3] [Reference Citation Analysis]
31 Suster D, Ronen S, Peterson JF, Mackinnon AC, Hes O, Suster S, Lin DI. MDM2 amplification and immunohistochemical expression in sarcomatoid renal cell carcinoma. Human Pathology 2019;87:28-36. [DOI: 10.1016/j.humpath.2019.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
33 Giraldo NA, Peske JD, Sautès-fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 2019;474:463-74. [DOI: 10.1007/s00428-018-02517-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
34 Huang T, Wang X, Yang X, Ji J, Wang Q, Yue X, Dong Z. Long Non-Coding RNA DUXAP8 Enhances Renal Cell Carcinoma Progression via Downregulating miR-126. Med Sci Monit 2018;24:7340-7. [PMID: 30317248 DOI: 10.12659/MSM.910054] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
35 El Mouallem N, Smith SC, Paul AK. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor. J Oncol Pract 2018;14:511-3. [PMID: 29920137 DOI: 10.1200/JOP.18.00213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]